119866

This is the Investigational New Drug (IND) number for , an interleukin-13 receptor antagonist developed by Dermira Inc. (and later Eli Lilly) for treating moderate-to-severe atopic dermatitis.

Targeted as a breakthrough therapy for skin conditions. 2. International Health (UNHCR Document 119866) 119866

It details findings regarding health services and community consultations for refugees, specifically in the Jordan region. 3. Commercial Real Estate & Market Research This is the Investigational New Drug (IND) number

This refers to the published by the United Nations High Commissioner for Refugees (UNHCR) in October 2025. 119866